SUPPLEMENTAL MATERIAL

Hyperdense artery sign, symptomatic infarct swelling and effect of alteplase in acute ischaemic stroke

Appendix I. IST-3 Collaborative Group

For a complete list of all committees, please see the IST-3 primary publication in The Lancet (The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischemic stroke (the third international stroke trial [IST-3]): a randomized controlled trial. Lancet 2012;379:2352-63).

CO-INVESTIGATORS

Peter Sandercock, DM (University of Edinburgh, Scotland, co-chief Investigator); Richard I Lindley, MD (Sydney Medical School – Westmead Hospital and The George Institute for Global Health, University of Sydney, Australia, co-chief Investigator); and Joanna M Wardlaw, MD (University of Edinburgh, Scotland, co-chief Investigator for neuroradiology).

CONTRIBUTORS

Trial Steering Committee

Colin Baigent (University of Oxford, UK, independent chairman); David Chadwick (University of Liverpool, UK, independent chairman); Pippa Tyrrell (University of Manchester, UK, independent member); Gordon Lowe (University of Glasgow, UK, independent member); Martin Dennis (University of Edinburgh, Scotland); Geoff Cohen (University of Edinburgh, Scotland, statistician); Karen Innes (University of Edinburgh, Scotland, trial coordinator); Heather Goodare (lay representative).

National coordinators and associate national coordinators

Australia: Richard I Lindley, MD (Sydney Medical School – Westmead Hospital and The George Institute for Global Health, University of Sydney, Australia); Graeme J Hankey (Royal Perth Hospital, Perth). Austria: Karl Matz (Landesklinikum Donnauegion Tulln, Tulln), Michael Brainin. Belgium: AP. Canada: Gord Gubitz (Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax), Stephen J Phillips (Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax). Italy: Stefano Ricci (Department of Neurology ASL1, Ospedale, Citta’ di Castello). Mexico: Antonio Arauz (Instituto Nacional de Neurologia, Mexico City). Norway: Eivind Berge (Oslo University Hospital, Oslo), Karsten Bruins Slot (Oslo University Hospital, Oslo). Poland: Anna Czlonkowska (Institute of Psychiatry and Neurology, Warsaw, and Medical University of Warsaw, Warsaw), Adam


CT and MRI reading panel

Joanna M Wardlaw, Andrew Farrall (University of Edinburgh, Scotland), Zoe Morris (University of Edinburgh, Scotland), Rüdiger von Kummer (Dresden University Stroke Centre, Germany), Lesley Cala (University of Western Australia, Crawley, Australia), Anders von Heijne (Dandyred Hospital, Stockholm, Sweden), Alessandro Adami (Sacro Cuore-Don Calabria Hospital, Verona, Italy), Andre Peeters (Cliniques Universitaires Saint-Luc, Bruxelles, Belgium), Gillian Potter (Salford Royal NHS Foundation Trust, England), Nick Braden (Neuroradiology, James Cook University Hospital, South Tees Hospital NHS Trust, Middlesborough, UK).

IST-3 collaborative group and participating hospitals in each country

Figures in parentheses are the number of patients recruited in the country or by the centre.


Appendix II. Funding sources for IST-3

The startup phase of IST-3 was supported by a grant from the Stroke Association, UK (TSA 04/99; Richard Lindley, Peter Sandercock, Joanna Wardlaw). The expansion phase was funded by the Health Foundation, UK (2268/1282; Peter Sandercock, Joanna Wardlaw). The main phase of the trial is funded by UK Medical Research Council (MRC) (grant numbers G0400069 and EME 09-800-15) and managed by NIHR on behalf of the MRC-NIHR partnership (Peter Sandercock, Joanna Wardlaw); the Research Council of Norway (Eivind Berge); Arbetsmarknadens Partners Forsakringsbolag (AFA) Insurances Sweden (Veronica Murray (deceased)); the Swedish Heart Lung Fund (Veronica Murray (deceased)); The Foundation of Marianne and Marcus Wallenberg, Stockholm County Council (Veronica Murray (deceased)); Karolinska Institute Joint ALF project grants Sweden (Veronica Murray (deceased)); the Polish Ministry of Science and Education (grant number 2PO5B10928; Anna Czlonkowska); the Australian Heart Foundation (Richard Lindley); Australian National Health and Medical Research Council (NHMRC) (Richard Lindley); the Swiss National Research Foundation (Phillippe Lyrer); the Swiss Heart Foundation (Phillippe Lyrer); the Foundation for Health and Cardio-/Neurovascular Research, Basel, Switzerland (Phillippe Lyrer); the Assessorato alla Sanità, Regione dell’Umbria, Italy (Stefano Ricci); and, Danube University, Krems, Austria (Karl Matz). Boehringer-Ingelheim GmbH donated drug and placebo for the 300 patients in the double-blind phase, but thereafter had no role in the trial. The UK Stroke Research Network (SRN study ID 2135) adopted the trial on 1/5/2006, supported the initiation of new UK sites, and in some centers, and, after that date, data collection was undertaken by staff funded by the network or working for associated NHS organizations. IST-3 acknowledges the support of the NIHR Stroke Research Network, NHS Research Scotland (NRS), through the Scottish Stroke Research Network, and the National Institute for Social Care and Health Research Clinical Research Centre (NISCHR CRC). The central imaging work was undertaken at the Brain Imaging Research Centre (www.sbric.ed.ac.uk), a member of the Scottish Imaging Network: A Platform for Scientific Excellence (SINAPSE) collaboration (www.sinapse.ac.uk; Joanna Wardlaw), at the Division of Clinical Neurosciences, University of Edinburgh. SINAPSE is funded by the Scottish Funding Council (SFC; Joanna Wardlaw) and the Chief Scientist Office of the Scottish Executive (CSO; Joanna Wardlaw). The scan reading development was funded by Chest, Heart and Stroke Scotland (R100/7; Joanna Wardlaw) with additional support from DesAcc, and University of Edinburgh.